Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids

Journal of Andrology

Volumn 20, Issue 3, 1999, Pages 348-355

  Lövgren, Janita ^a,d   Valtonen André, Camilla ^a   Marsal, Karel ^b,c   Lilja, Hans ^a   Lundwall, Åke ^a,c  

^a University Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer; Prostate; Protease

Indexed keywords

EPIDERMAL GROWTH FACTOR; NERVE GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN;

AMNION FLUID; ARTICLE; BIOASSAY; BODY FLUID; BREAST MILK; COLOSTRUM; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE; SALIVA; SEMINAL PLASMA;

AMNIOTIC FLUID; ANIMALS; BODY FLUIDS; CHROMATOGRAPHY, GEL; COLOSTRUM; EVOLUTION, MOLECULAR; FEMALE; HUMANS; KALLIKREINS; MALE; MICE; MILK, HUMAN; PHYLOGENY; PROSTATE-SPECIFIC ANTIGEN; SALIVA; SEMEN; TISSUE KALLIKREINS; VASOCONSTRICTOR AGENTS;

EID: 0033036413     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16:491-498.
2. Andriole GL, Catalona WJ. Prostate carcinoma. Anna Rev Med 1994;45: 351-359.
3. Baker AR, Shine J. Human kidney kallikrein: cDNA cloning and sequence analysis. DNA 1985;4:445-450.
4. Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H. Clinical utility of a novel highly sensitive and specific assay for human prostatic glandular kallikrein (hK2) in serum. J Urol (Suppl) 1997;157:441.
5. Bostwick D. Prostate-specific antigen, current role in diagnostic pathology of prostate cancer. Am J Clin Pathol (Suppl 1) 1994;102:531-537.
6. Chapdeline P, Paradis G, Tremblay RR, Dubé JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-208.
7. Charlesworth MC, Young CY, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 1997;49:487-493.
8. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M-T, Cockett ATK, Abrahamsson P-A, Lilja H. Serum prostate specific antigen complexed to alfal-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
9. Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 1994;99:C1-C6.
10. Clements JA, Mukthar A. Glandular kallikreins and the prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metabol 1994;78:1536-1539.
11. Clements JA, Mukthar A, Verity K, Pullar M, McNeill P, Cummins J, Fuller PJ. Kallikrein gene expression in human pituitary tissue. Clin Endocrinol 1996;44:223-231.
12. Corey E, Buhler KR, Vessella RL. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology 1997;50:567-571.
13. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:301-310.
14. Diamandis EP, Yu H. Non prostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24:275-282.
15. Drinkwater CC, Evans BA, Richards RI. Kallikreins, kinins and growth factor biosynthesis. Trends Biol Sci 1988;13:169-172.
16. Eerola R, Piironen T, Pettersson K, Lövgren J, Vehniainen M, Lilja H, Dowell B, Lövgren T, Karp M. Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Prostate 1997;31:84-90.
17. Evans BA, Richards RI. Genes for the alpha and gamma subunits of mouse nerve growth factor are contiguous. EMBO J 1985;4:133-138.
18. Fukushima D, Kitamura N, Nakanishi S. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 1985;24:8037-8043.
19. Gray A, Dull TJ, Ullrich A. Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor. Nature 1983;303:722-725.
20. Hsieh M-L, Charlesworth C, Goodmanson M., Zhang S, Seay T, Klee GG, Tindall DJ, and Young CYF (1997) Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 1997;57:13:897-899.
21. James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 1996;106:242-247.
22. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
23. Kimura M. The Neutral Theory of Molecular Evolution. Cambridge, United Kingdom: Cambridge University Press; 1983.
24. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus-Reichel K, Saedi MS. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996;56:5397-5402.
25. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-3114.
26. Levesque M, Yu H, D'Costa M, Tadross L, Diamandis EP. Immunore-active prostate-specific antigen in lung tumors. J Clin Lab Anal 1995; 9:375-379.
27. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Investig 1985;76:1899-1903.
28. Lilja H, Christensson A, Dahlén U, Matikainen M-T, Nilsson O, Pettersson K, Lövgren, T. Prostate-specific antigen in serum occurs predominantly in complex with alfa-antichymotrypsin. Clin Chem 1991;37: 1619-1625.
29. Lundwall Å, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-322.
30. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, Lilja H, Lundwall Å. Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Comm 1995;213:888-895.
31. Lövgren J, Rajakoski K, Karp M, Lundwall Å, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Comm 1997;238:549-555.
32. Melegos DN, Yu H, Allen LC, Diamandis EP. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996;29:555-562.
33. Mikolajczyk SD, Grauer LS, Miller LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997; 50:710-714.
34. Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997;158:1606-1609.
35. Oesterling JE. Prostate specific antigen: a critical assessment of the most usefultumor marker for adenocarcinoma of the prostate. J Urol 1991; 45:907-923.
36. Piironen T, Lövgren J, Karp M, Eerola R, Lundwall Å, Dowell B, Lövgren T, Lilja H, Pettersson K. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-1041.
37. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-425.
38. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-437.
39. Scott J, Urdea M, Quiroga M, Sanchez-Pescador R, Fong N, Selby M, Rutter WJ, Bell GI. Structure of a mouse submaxillary messenger RNA encoding epidermal growth factor and seven related proteins. Science 1983;221:236-240.
40. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-916.
41. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
42. Takagaki Y, Kitamura N, Nakanishi S. Cloning and sequence analysis of cDNA for human high molecular weight and low molecular weight prekininogens. Primary structure of the two human prekininogens. J Biol Chem 1985;260:8601-8609.
43. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997;272:21582-21588.
44. Taylor JM, Mitchell WM, Cohen S. Epidermal growth factor. Physical and chemical properties. J Biol Chem 1972;247:5928-5934.
45. van Leeuwen BH, Evans BA, Tregear GW, Richards RI. Mouse glandular kallikrein genes. Identification, structure, and expression of the renal kallikrein gene. J Biol Chem 1986;261:5529-5535.
46. Varon S, Nomura J, Shooter EM. The isolation of the mouse nerve growth factor protein in a high molecular weight form. Biochemistry 1967;6: 2202-2209.
47. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a prostate specific antigen. Investig Urol 1979;17:159-163.
48. Watt KWK, Lee P-J, M'Timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
49. Wolff JM, Borchers H, Kunitz O, Planz B, Jakse G. Prostate-specific antigen immunoreactivity in spinal fluid. Urol Int 1997;59:236-238.
50. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27:75-79.
51. Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995a;41:204-210.
52. Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995b;41:54-58.
53. Zarghami N, Levesque M, D'Costa M, Angelopoulou K, Diamandis EP. Frequency of expression of prostate-specific antigen mRNA in lung tumors. Am J Clin Pathol 1997;108:184-190.